Merry Life Launches Global Phase II Trial of TML-6, The First Drug Targeted at Autolysosome pathway for Therapy of Alzheimer’s Disease
TAINAN, June 13, 2025 /PRNewswire/ -- Merry Life Biomedical Company announces the…
Alamar Biosciences, Alzheimer’s Disease Data Initiative, and Gates Ventures Unite in Global Partnership to Advance Translational Research in Alzheimer’s Disease.
Multi-center project will profile over 40,000 samples using ultra-sensitive NULISA™ technology. FREMONT,…
Press Release: Sanofi to acquire Vigil Neuroscience, Inc., adding a new investigational medicine to treat Alzheimers disease to the neurology pipeline
Sanofi to acquire Vigil Neuroscience, Inc., adding a new investigational medicine to…
Global Alzheimers Platform Foundation ApplaudsFDA Authorization of the First Blood-Based Diagnostic Test for Assessing Alzheimers Disease
WASHINGTON, May 20, 2025 (GLOBE NEWSWIRE) -- The Global Alzheimer’s Platform Foundation®…
Anavex Life Sciences Announces Positive up to 4-Years Oral Blarcamesine Results from Phase IIb/III Open-Label Extension Trial in Early Alzheimers Disease
ATTENTION-AD trial data through 192 weeks presented at AD/PDTM 2025 Conference Prespecified…
Study Finds Brain Training Also Helps Caregivers of Dementia Patients
SAN FRANCISCO, April 01, 2025 (GLOBE NEWSWIRE) -- While a particular brain…
Annovis Provides Corporate Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial Results
March 21, 2025 17:05 ET | Source: Annovis Bio Inc. MALVERN, Pa.,…
Longeveron Announces Full-Year 2024 Financial Results and Provides Business Update
Pivotal Phase 2b clinical trial (ELPIS II) evaluating Lomecel-B™ (laromestrocel) in Hypoplastic Left…
NKGen Biotech Announces Publication of Phase 1 Troculeucel Clinical Trial Results for the Treatment of Alzheimers Disease
February 13, 2025 08:00 ET | Source: NKGen Biotech The results from…
Annovis Bio, Inc. Announces Closing of $21 Million Public Offering
MALVERN, PA, Feb. 04, 2025 (GLOBE NEWSWIRE) -- via IBN - Annovis Bio,…